CGTLive’s Weekly Rewind – September 16, 2022
Review top news and interview highlights from the week ending September 16, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma
MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.
2. Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors
Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.
3. Ide-Cel to Be Evaluated in Newly Diagnosed Multiple Myeloma
The announcement comes after positive top-line results in the ongoing KarMMa-3 study.
4. ICER Throws Support Behind Clinical, Cost Value of Hemophilia Gene Therapies in Draft Report
A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.
5. Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
